| Literature DB >> 18989635 |
Dai Maruyama1, Takashi Watanabe2, Yuji Heike1, Kumiko Nagase1, Noriko Takahashi1, Satoshi Yamasaki1, Fusako Waki1, Hiroki Yokoyama1, Sung-Won Kim1, Yukio Kobayashi1, Shin Aizawa3, Kensei Tobinai1.
Abstract
Bortezomib blocks the activation of nuclear factor-kappaB-mediated pro-inflammatory cytokines, however, systemic inflammatory symptoms following bortezomib administration have been reported, although their mechanisms remain elusive. Serum samples were obtained from five patients, who participated in a phase I/II study of Japanese patients with relapsed or refractory multiple myeloma (MM), and developed cyclic fever following bortezomib administration, to measure cytokine levels. Significant correlations between interleukin (IL)-6 or interferon (IFN)-gamma and the body temperature were observed in two patients each. Furthermore, we found that IL-6 elevation was not observed after the addition of bortezomib to any examined MM cells alone, but was noted in a case of bone marrow stromal cells (BMSCs) of macrophage origin alone or co-cultured with MM cells. Similarly, a marked increase in IFN-gamma levels was induced by adding bortezomib to BMSCs of fibroblast origin. Although this investigation was a preliminary study with a small number of patients, our results suggested that pro-inflammatory cytokines causing bortezomib-associated fever were secreted from BMSCs rather than MM cells.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18989635 DOI: 10.1007/s12185-008-0194-0
Source DB: PubMed Journal: Int J Hematol ISSN: 0925-5710 Impact factor: 2.490